Key facts
- This page summarizes ELI LILLY & Co's Form 3 filing for Aktis Oncology, Inc. (AKTS).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 15 Jan 2026, 06:01.
ELI LILLY & Co - 12 Jan 2026 Form 3 Insider Report for Aktis Oncology, Inc. (AKTS)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- AKTS
- Reported as of
- 12 Jan 2026
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 15 Jan 2026, 06:01:45 UTC
- Prior SEC filing
- 14 Aug 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christopher Anderson, Vice President, Leader of Corporate Securities and Assistant Corporate Secretary
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
ELI LILLY & Co filed Form 3 for Aktis Oncology, Inc. (AKTS) on 15 Jan 2026.
Change
- Previous filing in this sequence was filed on 14 Aug 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0000059478
Primary reporting owner
ELI LILLY & Co
- Relationship
- 10%+ Owner
- Address
- LILLY CORPORATE CENTER, INDIANAPOLIS
- Signature
- /s/ Christopher Anderson, Vice President, Leader of Corporate Securities and Assistant Corporate Secretary
- Signature date
- 15 Jan 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AKTS
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 6,344,114
- Date
- 12 Jan 2026
- Ownership
- Direct
* marks a reported price that did not pass the local price check.